Therefore, baseline characteristics such as duration of CP-CML, sequence of prior TKIs, and detailed history of resistance or intolerance to a specific TKI could not be included to account for differences in enrolled populations. This evidence concerns the gene CP and chronic myelogenous leukemia, BCR-ABL1 positive.